O'Reilly logo

The End of Accounting and the Path Forward for Investors and Managers by Feng Gu, Baruch Lev

Stay ahead with the world's most comprehensive technology and business learning platform.

With Safari, you learn the way you learn best. Get unlimited access to videos, live online training, learning paths, books, tutorials, and more.

Start Free Trial

No credit card required

Chapter 10Sins of Omission and Commission

The Missing Accounting Link

On September 20, 2013, the Dutch biotech company Prosensa Holding NV announced that its muscular dystrophy experimental drug Drisapersen failed to help patients more than a placebo. This is the nightmare of every drug and biotech company, and indeed, investors' reaction was swift and harsh: Prosensa's stock plunged 70 percent on the announcement of the trial's failure. It was not a total loss, though, since the stock of Sarepta Therapeutics Inc., a competing biotech firm developing an alternative muscular dystrophy drug increased 18 percent on Prosensa's failure announcement. One company's loss is another's gain. Large drug companies, with diversified portfolios of drugs under development, aren't hit as hard by clinical test failures, but they are hit nevertheless. The large British pharmaceutical company ...

With Safari, you learn the way you learn best. Get unlimited access to videos, live online training, learning paths, books, interactive tutorials, and more.

Start Free Trial

No credit card required